Jun 26 |
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
|
Jun 13 |
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
|
Jun 5 |
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
|
May 9 |
VYNE Therapeutics GAAP EPS of -$0.15 beats by $0.09, revenue of $0.01M misses by $0.09M
|
May 9 |
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 6 |
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
|
May 1 |
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
|
Apr 13 |
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans
|
Mar 19 |
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
Mar 3 |
VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|